Results of the EV-103 Study in Patients With Advanced Urothelial Carcinoma

The ADVANCED-2 trial plans to build onto the early antitumor and safety data seen with TARA-002 that were presented this year for patients with non-muscle invasive bladder cancer.

Seagen Inc., and Astellas Pharma Inc., report that both primary end points of the phase 3 EV-302 clinical trial have been met.

In an interview with Targeted Oncology, Arlene O. Siefker-Radtke, MD, discusses the findings from 3 trials of erdafitinib and explains the next steps for evaluating the agent.

Nadofaragene firadenovec-vncg received FDA approval for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer in 2022, and is now being evaluated further in the ABLE-41 trial.

Promising overall survival findings from cohort 1 of the THOR study evaluating erdafitinib in locally advanced or metastatic urothelial cancer have pushed the agent’s developer to submit an sNDA seeking its full approval.

A single-arm trial induced high event-free and overall survival with the addition of durvalumab to standard of care before radical surgery in patients with muscle-invasive urothelial carcinoma.